St. Luke's Hospital in Bethlehem, PA, will offer what it's calling a first-of-its-kind clinical guarantee on robot-assisted radical prostatectomies.
St. Luke’s Hospital in Bethlehem, PA, will offer what it’s calling a first-of-its-kind clinical guarantee on robot-assisted radical prostatectomies.
St. Luke’s and its urologic surgeons said they have developed and will adhere to a rigorous set of clinical guidelines for every surgery. If St. Luke’s and its surgeons do not follow these guidelines every time, or if a patient develops specific complications directly related to the robotic prostatectomy within 30 days of surgery, the patient and his insurance company will not be billed for services rendered, the hospital said.
The clinical guidelines were designed by St. Luke’s urologists Eric Mayer, MD, and Joseph Lennert, MD. Urologic surgeons at St. Luke’s have been performing minimally invasive robot-assisted surgery using the da Vinci Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) since 2003.
“St. Luke’s administration challenged us to develop a program that took ‘pay for performance’ to the next level, exceeding the standards for quality care that we are required to adhere to today,” Dr. Mayer said. “We believe that prostate surgery could be approached in a manner that combined our clinical expertise, our advanced technology, and our interest in adhering to clinical protocols in such a way as to offer an actual guarantee for services rendered.”
The urologists devised procedures to ensure steps would always be followed, regardless of which surgeon provided care.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.